Edwards Lifesciences Corporation
EW
$85.28
-$1.90-2.18%
NYSE
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Net Income | -68.67% | -12.64% | -6.93% | -7.16% | -- |
| Total Depreciation and Amortization | 8.93% | 2.89% | 4.10% | -14.29% | -- |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 23.67% | -43.16% | 1,029.11% | 108.52% | -- |
| Change in Net Operating Assets | 31.97% | 213.15% | -39.48% | 73.63% | -- |
| Cash from Operations | -21.40% | 97.69% | 3.50% | 319.92% | -136.24% |
| Capital Expenditure | -69.39% | -16.63% | 11.96% | -12.45% | -- |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 61.27% | -201.55% | -186.91% | 103.40% | -- |
| Cash from Investing | 53.65% | -148.58% | -301.76% | 114.79% | -121.35% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | -6.92% | -39.34% | 14.63% | 74.48% | -- |
| Repurchase of Common Stock | 92.46% | -9,694.55% | 98.22% | -308,500.00% | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | 98.69% | -23,710.00% | 42.86% | 600.00% | -- |
| Cash from Financing | 98.46% | -1,504.36% | 120.43% | -1,002.10% | 102.93% |
| Foreign Exchange rate Adjustments | 450.00% | 96.62% | -67.23% | -134.71% | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 141.11% | -521.53% | 56.89% | 114.41% | -130.84% |